{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:44Z","timestamp":1786981544116,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA023356"],"award-info":[{"award-number":["T32 DA023356"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DP2DA049295"],"award-info":[{"award-number":["DP2DA049295"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Allergy and Infectious Diseases\/National Institute on Drug Abuse","award":["R01AI417490"],"award-info":[{"award-number":["R01AI417490"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We aimed to estimate health state utility values (HSUVs) for the key health states found in opioid use disorder (OUD) cost-effectiveness models in the published literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data obtained from six trials representing 1,777 individuals with OUD. We implemented mapping algorithms to harmonize data from different measures of quality of life (the SF-12 Versions 1 and 2 and the EQ-5D-3\u00a0L). We performed a regression analysis to quantify the relationship between HSUVs and the following variables: days of extra-medical opioid use in the past 30 days, injecting behaviors, treatment with medications for OUD, HIV status, and age. A secondary analysis explored the impact of opioid withdrawal symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were statistically significant reductions in HSUVs associated with extra-medical opioid use (-0.002 (95% CI [-0.003,-0.0001]) to -0.003 (95% CI [-0.005,-0.002]) per additional day of heroin or other opiate use, respectively), drug injecting compared to not injecting (-0.043 (95% CI [-0.079,-0.006])), HIV-positive diagnosis compared to no diagnosis (-0.074 (95% CI [-0.143,-0.005])), and age (-0.001 per year (95% CI [-0.003,-0.0002])). Parameters associated with medications for OUD treatment were not statistically significant after controlling for extra-medical opioid use (0.0131 (95% CI [-0.0479,0.0769])), in line with prior studies. The secondary analysis revealed that withdrawal symptoms are a fundamental driver of HSUVs, with predictions of 0.817 (95% CI [0.768, 0.858]), 0.705 (95% CI [0.607, 0.786]), and 0.367 (95% CI [0.180, 0.575]) for moderate, severe, and worst level of symptoms, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We observed HSUVs for OUD that were higher than those from previous studies that had been conducted without input from people living with the condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11136-024-03729-6","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T10:02:42Z","timestamp":1723111362000},"page":"2783-2796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Analyzing quality of life among people with opioid use disorder from the National Institute on Drug Abuse Data Share initiative: implications for decision making"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5134-3308","authenticated-orcid":false,"given":"Thomas","family":"Patton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan R.","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Marienfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Borquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"3729_CR1","unstructured":"National Center for Health Statistics (2021). Products-vital statistics rapid release-provisional drug overdose data. Centers for Disease Control and Prevention. Retrieved from https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm#dashboard"},{"issue":"5","key":"3729_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/10826084.2022.2026969","volume":"57","author":"T Patton","year":"2022","unstructured":"Patton, T., Revill, P., Sculpher, M., & Borquez, A. (2022). Using economic evaluation to inform responses to the opioid epidemic in the United States: Challenges and suggestions for Future Research. Substance use & Misuse, 57(5), 815\u2013821.","journal-title":"Substance use & Misuse"},{"key":"3729_CR3","doi-asserted-by":"crossref","unstructured":"Briggs, A., Sculpher, M., & Claxton, K. (2006). Decision modelling for health economic evaluation. Oup Oxford.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"3729_CR4","doi-asserted-by":"crossref","unstructured":"Wolowacz, S. E., Briggs, A., Belozeroff, V., Clarke, P., Doward, L., Goeree, R., \u2026 Norman, R. (2016). Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value in Health, 19(6), 704\u2013719.","DOI":"10.1016\/j.jval.2016.06.001"},{"issue":"8","key":"3729_CR5","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.jval.2020.03.015","volume":"23","author":"C Barbosa","year":"2020","unstructured":"Barbosa, C., Dowd, W. N., & Zarkin, G. (2020). Economic evaluation of interventions to address opioid misuse: A systematic review of methods used in simulation modeling studies. Value in Health, 23(8), 1096\u20131108.","journal-title":"Value in Health"},{"key":"3729_CR6","doi-asserted-by":"crossref","unstructured":"Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., \u2026 others. (2007). Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. NIHR Health Technology Assessment programme: Executive Summaries.","DOI":"10.3310\/hta11090"},{"issue":"8","key":"3729_CR7","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/j.1524-4733.2009.00581.x","volume":"12","author":"R Norman","year":"2009","unstructured":"Norman, R., Cronin, P., Viney, R., King, M., Street, D., & Ratcliffe, J. (2009). International comparisons in valuing EQ-5D health states: A review and analysis. Value in Health, 12(8), 1194\u20131200.","journal-title":"Value in Health"},{"issue":"4","key":"3729_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/add.13219","volume":"111","author":"E Wittenberg","year":"2016","unstructured":"Wittenberg, E., Bray, J. W., Aden, B., Gebremariam, A., Nosyk, B., & Schackman, B. R. (2016). Measuring benefits of opioid misuse treatment for economic evaluation: Health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population. Addiction, 111(4), 675\u2013684.","journal-title":"Addiction"},{"issue":"4","key":"3729_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/1740774518769655","volume":"15","author":"V Huser","year":"2018","unstructured":"Huser, V., & Shmueli-Blumberg, D. (2018). Data sharing platforms for de-identified data from human clinical trials. Clinical Trials, 15(4), 413\u2013423.","journal-title":"Clinical Trials"},{"key":"3729_CR10","doi-asserted-by":"crossref","unstructured":"Conner-Spady, B., & Suarez-Almazor, M. E. (2003). Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Medical care, 791\u2013801.","DOI":"10.1097\/00005650-200307000-00003"},{"issue":"8","key":"3729_CR11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jval.2014.11.002","volume":"17","author":"B Pennington","year":"2014","unstructured":"Pennington, B., & Davis, S. (2014). Mapping from the Health Assessment Questionnaire to the EQ-5D: The impact of different algorithms on cost-effectiveness results. Value in Health, 17(8), 762\u2013771.","journal-title":"Value in Health"},{"issue":"11","key":"3729_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40273-015-0310-y","volume":"33","author":"T Peasgood","year":"2015","unstructured":"Peasgood, T., & Brazier, J. (2015). Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values? Pharmacoeconomics, 33(11), 1101\u20131105.","journal-title":"Pharmacoeconomics"},{"key":"3729_CR13","doi-asserted-by":"publisher","first-page":"108146","DOI":"10.1016\/j.jsat.2020.108146","volume":"119","author":"K Cioe","year":"2020","unstructured":"Cioe, K., Biondi, B. E., Easly, R., Simard, A., Zheng, X., & Springer, S. A. (2020). A systematic review of patients\u2019 and providers\u2019 perspectives of medications for treatment of opioid use disorder. Journal of Substance Abuse Treatment, 119, 108146.","journal-title":"Journal of Substance Abuse Treatment"},{"key":"3729_CR14","doi-asserted-by":"crossref","unstructured":"Hoffman, K. A., Baker, R., Fanucchi, L. C., Lum, P. J., Kunkel, L. E., Ponce Terashima, J., \u2026 Korthuis, P. T. (2021). Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. Addiction Science & Clinical Practice, 16(1), 1\u20139.","DOI":"10.1186\/s13722-021-00277-z"},{"issue":"5","key":"3729_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/dar.12939","volume":"38","author":"J Neale","year":"2019","unstructured":"Neale, J., Tompkins, C. N., & Strang, J. (2019). Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences. Drug and Alcohol Review, 38(5), 510\u2013518.","journal-title":"Drug and Alcohol Review"},{"key":"3729_CR16","doi-asserted-by":"crossref","unstructured":"Beaulieu, E., DiGennaro, C., Stringfellow, E., Connolly, A., Hamilton, A., Hyder, A., \u2026 Jalali, M. S. (2021). Economic evaluation in opioid modeling: systematic review. Value in Health, 24(2), 158\u2013173.","DOI":"10.1016\/j.jval.2020.07.013"},{"issue":"7","key":"3729_CR17","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jval.2020.12.023","volume":"24","author":"EN Onuoha","year":"2021","unstructured":"Onuoha, E. N., Leff, J. A., Schackman, B. R., McCollister, K. E., Polsky, D., & Murphy, S. M. (2021). Economic evaluations of pharmacologic treatment for opioid use disorder: A systematic literature review. Value in Health, 24(7), 1068\u20131083.","journal-title":"Value in Health"},{"key":"3729_CR18","unstructured":"American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (Vol. 4). Washington, DC: American Psychiatric Association."},{"issue":"4","key":"3729_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jval.2019.12.002","volume":"23","author":"M Acharya","year":"2020","unstructured":"Acharya, M., Chopra, D., Hayes, C. J., Teeter, B., & Martin, B. C. (2020). Cost-effectiveness of intranasal naloxone distribution to high-risk prescription opioid users. Value in Health, 23(4), 451\u2013460.","journal-title":"Value in Health"},{"key":"3729_CR20","unstructured":"20. \tDakin, H., Abel, L., Burns, R., Koleva-Kolarova, R., & Yang, Y. (n.d.). Dakin H, Abel, L, Burns R, Koleva-Kolarova R, Yang Y, 2023. HERC database of mapping studies, Version 9.0 (Last updated: 1st December 2023). Retrieved May 3, 2024, from http:\/\/www.herc.ox.ac.uk\/downloads\/herc-database-of-mapping-studies."},{"issue":"9","key":"3729_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1046\/j.1360-0443.2001.96912676.x","volume":"96","author":"PG Barnett","year":"2001","unstructured":"Barnett, P. G., Zaric, G. S., & Brandeau, M. L. (2001). The cost\u2013effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction, 96(9), 1267\u20131278.","journal-title":"Addiction"},{"issue":"8","key":"3729_CR22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/13696998.2017.1341416","volume":"20","author":"JA Carter","year":"2017","unstructured":"Carter, J. A., Dammerman, R., & Frost, M. (2017). Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder. Journal of Medical Economics, 20(8), 893\u2013901.","journal-title":"Journal of Medical Economics"},{"issue":"7","key":"3729_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/13696998.2017.1325744","volume":"20","author":"J Kenworthy","year":"2017","unstructured":"Kenworthy, J., Yi, Y., Wright, A., Brown, J., Madrigal, M., A., & Dunlop, W. C. (2017). Use of opioid substitution therapies in the treatment of opioid use disorder: Results of a UK cost-effectiveness modelling study. Journal of Medical Economics, 20(7), 740\u2013748.","journal-title":"Journal of Medical Economics"},{"issue":"3","key":"3729_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/add.14797","volume":"115","author":"O Morozova","year":"2020","unstructured":"Morozova, O., Crawford, F. W., Cohen, T., Paltiel, A. D., & Altice, F. L. (2020). Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: Dynamic modeling analysis. Addiction, 115(3), 437\u2013450.","journal-title":"Addiction"},{"key":"3729_CR25","doi-asserted-by":"crossref","unstructured":"Lu, G., Kounali, D., & Ades, A. (2014). Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale. Value in Health, 17(2), 280\u2013287.","DOI":"10.1016\/j.jval.2013.12.006"},{"issue":"5","key":"3729_CR26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/AOG.0000000000003503","volume":"134","author":"A Premkumar","year":"2019","unstructured":"Premkumar, A., Grobman, W. A., Terplan, M., & Miller, E. S. (2019). Methadone, buprenorphine, or detoxification for management of perinatal opioid use disorder: A cost-effectiveness analysis. Obstetrics and Gynecology, 134(5), 921.","journal-title":"Obstetrics and Gynecology"},{"key":"3729_CR27","unstructured":"Ware, J., Kosinski, M., & Keller, S. (1998). SF12: How to score the SF-12 physical and mental summary scales. QualityMetric, Inc."},{"issue":"6","key":"3729_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","volume":"27","author":"BR Schackman","year":"2012","unstructured":"Schackman, B. R., Leff, J. A., Polsky, D., Moore, B. A., & Fiellin, D. A. (2012). Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. Journal of General Internal Medicine, 27(6), 669\u2013676.","journal-title":"Journal of General Internal Medicine"},{"key":"3729_CR29","unstructured":"Agency for Healthcare Research and Quality. (n.d.). MEPS HC-060: 2001 Full Year Consolidated Data File. Retrieved from https:\/\/www.meps.ahrq.gov\/mepsweb\/data_stats\/download_data_files_detail.jsp?cboPufNumber=HC-060"},{"key":"3729_CR30","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.drugpo.2019.07.031","volume":"75","author":"T Townsend","year":"2020","unstructured":"Townsend, T., Blostein, F., Doan, T., Madson-Olson, S., Galecki, P., & Hutton, D. W. (2020). Cost-effectiveness analysis of alternative naloxone distribution strategies: First responder and lay distribution in the United States. International Journal of Drug Policy, 75, 102536.","journal-title":"International Journal of Drug Policy"},{"issue":"7","key":"3729_CR31","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2105\/AJPH.90.7.1100","volume":"90","author":"GS Zaric","year":"2000","unstructured":"Zaric, G. S., Barnett, P. G., & Brandeau, M. L. (2000). HIV transmission and the cost-effectiveness of methadone maintenance. American Journal of Public Health, 90(7), 1100.","journal-title":"American Journal of Public Health"},{"issue":"8","key":"3729_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1287\/mnsc.46.8.1013.12025","volume":"46","author":"GS Zaric","year":"2000","unstructured":"Zaric, G. S., Brandeau, M. L., & Barnett, P. G. (2000). Methadone maintenance and HIV prevention: A cost-effectiveness analysis. Management Science, 46(8), 1013\u20131031.","journal-title":"Management Science"},{"issue":"3","key":"3729_CR33","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/S2468-2667(17)30006-3","volume":"2","author":"J Uyei","year":"2017","unstructured":"Uyei, J., Fiellin, D. A., Buchelli, M., Rodriguez-Santana, R., & Braithwaite, R. S. (2017). Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: A cost-effectiveness modelling study. The Lancet Public Health, 2(3), e133\u2013e140.","journal-title":"The Lancet Public Health"},{"key":"3729_CR34","doi-asserted-by":"crossref","unstructured":"Boys, A., Marsden, J., Fountain, J., Griffiths, P., Stillwell, G., & Strang, J. (1999). What influences young people\u2019s use of drugs? A qualitative study of decision-making. Drugs: education, prevention and policy, 6(3), 373\u2013387.","DOI":"10.1080\/09687639997052"},{"key":"3729_CR35","unstructured":"American Psychiatric Association. (1994). Diagnostic and statistical Manual of Mental disorders (Fourth Edition) (Vol. 4). American Psychiatric Association."},{"key":"3729_CR36","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, & Association, A. (2013). A. P., & others. Diagnostic and statistical manual of mental disorders: DSM-5 (Vol. 10). Washington, DC: American psychiatric association.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"3729_CR37","unstructured":"Dakin, H., Abel, L., Burns, R., Koleva-Kolarova, R., Yang, Y. (n.d.)., Dakin, H., Abel, L., Burns, R., Koleva-Kolarova, R., & Yang, Y. (2023). HERC database of mapping studies, Version 9.0 (Last updated: 1st December 2023). Retrieved May 3, 2024, from http:\/\/www.herc.ox.ac.uk\/downloads\/herc-database-of-mapping-studies"},{"key":"3729_CR38","unstructured":"Arel-Bundock, V. (2023). marginaleffects: Predictions, Comparisons, Slopes, Marginal Means, and Hypothesis Tests. Retrieved from https:\/\/marginaleffects.com\/"},{"key":"3729_CR39","doi-asserted-by":"crossref","unstructured":"Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical care, 203\u2013220.","DOI":"10.1097\/00005650-200503000-00003"},{"issue":"7","key":"3729_CR40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1177\/0272989X15577362","volume":"35","author":"M Coca Perraillon","year":"2015","unstructured":"Coca Perraillon, M., Shih, Y. C. T., & Thisted, R. A. (2015). Predicting the EQ-5D-3L preference index from the SF-12 health survey in a national US sample: A finite mixture approach. Medical Decision Making, 35(7), 888\u2013901.","journal-title":"Medical Decision Making"},{"key":"3729_CR41","doi-asserted-by":"crossref","unstructured":"Franks, P., Lubetkin, E. I., Gold, M. R., & Tancredi, D. J. (2003). Mapping the SF-12 to preference-based instruments: Convergent validity in a low-income, minority population. Medical Care, 1277\u20131283.","DOI":"10.1097\/01.MLR.0000093480.58308.D8"},{"issue":"2","key":"3729_CR42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jval.2013.12.006","volume":"17","author":"G Lu","year":"2014","unstructured":"Lu, G., Kounali, D., & Ades, A. (2014). Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale. Value in Health, 17(2), 280\u2013287.","journal-title":"Value in Health"},{"issue":"2","key":"3729_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1192\/bjp.bp.115.165530","volume":"209","author":"JR B\u00f6hnke","year":"2016","unstructured":"B\u00f6hnke, J. R., & Croudace, T. J. (2016). Calibrating well-being, quality of life and common mental disorder items: Psychometric epidemiology in public mental health research. The British Journal of Psychiatry, 209(2), 162\u2013168.","journal-title":"The British Journal of Psychiatry"},{"key":"3729_CR44","unstructured":"Ware, J., Kosinski, M., & Keller, S. (1998). SF12: How to score the SF-12 Physical and Mental Summary scales. QualityMetric. Inc."},{"key":"3729_CR45","unstructured":"Kosinski, M., Ware, J. E., Turner-Bowker, D. M., & Gandek, B. (2007). User\u2019s manual for the SF-12v2 health survey: with a supplement documenting the SF-12\u00aehealth survey. QualityMetric Incorporated."},{"key":"3729_CR46","unstructured":"Agency for Healthcare Research and Quality (n.d.). MEPS HC-060: 2001 Full Year Consolidated Data File. Retrieved from https:\/\/www.meps.ahrq.gov\/mepsweb\/data_stats\/download_data_files_detail.jsp?cboPufNumber=HC-060"},{"key":"3729_CR47","unstructured":"Agency for Healthcare Research and Quality. (n.d.). MEPS HC-079: 2003 Full Year Consolidated Data File. Retrieved September 28 (2022). from https:\/\/www.meps.ahrq.gov\/mepsweb\/data_stats\/download_data_files_detail.jsp?cboPufNumber=HC-079"},{"issue":"10","key":"3729_CR48","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-015-0312-9","volume":"33","author":"S Petrou","year":"2015","unstructured":"Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., Froud, R., & Gray, A. (2015). The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: Explanation and elaboration. Pharmacoeconomics, 33(10), 993\u20131011.","journal-title":"Pharmacoeconomics"},{"key":"3729_CR49","doi-asserted-by":"crossref","unstructured":"Sprangers, M. A., & Schwartz, C. E. (1999). Integrating response shift into health-related quality of life research: a theoretical model. Social Science & Medicine, 48(11), 1507\u20131515.","DOI":"10.1016\/S0277-9536(99)00045-3"},{"issue":"1","key":"3729_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-12-144","volume":"12","author":"M Hunger","year":"2012","unstructured":"Hunger, M., D\u00f6ring, A., & Holle, R. (2012). Longitudinal beta regression models for analyzing health-related quality of life scores over time. BMC Medical Research Methodology, 12(1), 1\u201312.","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"3729_CR51","first-page":"373","volume":"6","author":"A Boys","year":"1999","unstructured":"Boys, A., Marsden, J., Fountain, J., Griffiths, P., Stillwell, G., & Strang, J. (1999). What influences young people\u2019s use of drugs? A qualitative study of decision-making. Drugs: Education Prevention and Policy, 6(3), 373\u2013387.","journal-title":"Drugs: Education Prevention and Policy"},{"issue":"3","key":"3729_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0167-6296(98)00039-3","volume":"18","author":"K Claxton","year":"1999","unstructured":"Claxton, K. (1999). The irrelevance of inference: A decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics, 18(3), 341\u2013364.","journal-title":"Journal of Health Economics"},{"issue":"4","key":"3729_CR53","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1177\/0272989X11406986","volume":"31","author":"CH Jackson","year":"2011","unstructured":"Jackson, C. H., Bojke, L., Thompson, S. G., Claxton, K., & Sharples, L. D. (2011). A framework for addressing structural uncertainty in decision models. Medical Decision Making, 31(4), 662\u2013674.","journal-title":"Medical Decision Making"},{"issue":"2","key":"3729_CR54","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/1536867X1201200209","volume":"12","author":"R Williams","year":"2012","unstructured":"Williams, R. (2012). Using the margins command to estimate and interpret adjusted predictions and marginal effects. The Stata Journal, 12(2), 308\u2013331.","journal-title":"The Stata Journal"},{"key":"3729_CR55","unstructured":"Arel-Bundock, V. (2023). marginaleffects: Predictions, Comparisons, Slopes, Marginal Means, and Hypothesis Tests. Retrieved from https:\/\/marginaleffects.com\/"},{"key":"3729_CR56","doi-asserted-by":"crossref","unstructured":"Szende, A., Janssen, B., & Cabases, J. (2014). Self-reported population health: an international perspective based on EQ-5D.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"3729_CR57","doi-asserted-by":"crossref","unstructured":"Forsat, N. D., Palmowski, A., Palmowski, Y., Boers, M., & Buttgereit, F. (2020). Recruitment and retention of older people in clinical research: a systematic literature review. Journal of the American Geriatrics Society, 68(12), 2955\u20132963.","DOI":"10.1111\/jgs.16875"},{"key":"3729_CR58","doi-asserted-by":"crossref","unstructured":"Feeny, D., Krahn, M., Prosser, L. A., & Salomon, J. A. (2016). Valuing health outcomes. Cost-effectiveness in health and medicine (pp. 167\u2013201). Oxford University Press Oxford.","DOI":"10.1093\/acprof:oso\/9780190492939.003.0007"},{"key":"3729_CR59","unstructured":"ICER. (2020). ICER\u2019s reference case for economic evaluations: Principles and rationale. Institute for Clinical and Economic Review Boston."},{"issue":"7","key":"3729_CR60","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/hec.1093","volume":"15","author":"MJ Sculpher","year":"2006","unstructured":"Sculpher, M. J., Claxton, K., Drummond, M., & McCabe, C. (2006). Whither trial-based economic evaluation for health care decision making? Health Economics, 15(7), 677\u2013687.","journal-title":"Health Economics"},{"key":"3729_CR61","doi-asserted-by":"crossref","unstructured":"Ciani, O., Buyse, M., Drummond, M., Rasi, G., Saad, E. D., & Taylor, R. S. (2017). Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value in Health, 20(3), 487\u2013495.","DOI":"10.1016\/j.jval.2016.10.011"},{"key":"3729_CR62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jsat.2016.05.001","volume":"67","author":"E Krebs","year":"2016","unstructured":"Krebs, E., Kerr, T., Wood, E., & Nosyk, B. (2016). Characterizing long-term health related quality of life trajectories of individuals with opioid use disorder. Journal of Substance Abuse Treatment, 67, 30\u201337.","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"3729_CR63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/02791072.2015.1014948","volume":"47","author":"SG Mitchell","year":"2015","unstructured":"Mitchell, S. G., Gryczynski, J., Schwartz, R. P., Myers, C. P., O\u2019Grady, K. E., Olsen, Y. K., & Jaffe, J. H. (2015). Changes in quality of life following buprenorphine treatment: Relationship with treatment retention and illicit opioid use. Journal of Psychoactive Drugs, 47(2), 149\u2013157.","journal-title":"Journal of Psychoactive Drugs"},{"issue":"11","key":"3729_CR64","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/S0277-9536(99)00045-3","volume":"48","author":"MA Sprangers","year":"1999","unstructured":"Sprangers, M. A., & Schwartz, C. E. (1999). Integrating response shift into health-related quality of life research: A theoretical model. Social Science & Medicine, 48(11), 1507\u20131515.","journal-title":"Social Science & Medicine"},{"key":"3729_CR65","doi-asserted-by":"crossref","unstructured":"Bansback, N., Guh, D., Oviedo-Joekes, E., Brissette, S., Harrison, S., Janmohamed, A., \u2026 others. (2018). Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction, 113(7), 1264\u20131273.","DOI":"10.1111\/add.14171"},{"issue":"4","key":"3729_CR66","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s11136-022-03304-x","volume":"32","author":"PA Powell","year":"2023","unstructured":"Powell, P. A., Karimi, M., Rowen, D., Devlin, N., van Hout, B., & Brazier, J. E. (2023). Hypothetical versus experienced health state valuation: A qualitative study of adult general public views and preferences. Quality of Life Research, 32(4), 1187\u20131197.","journal-title":"Quality of Life Research"},{"key":"3729_CR67","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","volume":"74","author":"SM Silverstein","year":"2019","unstructured":"Silverstein, S. M., Daniulaityte, R., Martins, S. S., Miller, S. C., & Carlson, R. G. (2019). Everything is not right anymore: Buprenorphine experiences in an era of illicit fentanyl. International Journal of Drug Policy, 74, 76\u201383.","journal-title":"International Journal of Drug Policy"},{"issue":"6","key":"3729_CR68","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/15563650.2022.2032730","volume":"60","author":"A Spadaro","year":"2022","unstructured":"Spadaro, A., Sarker, A., Hogg-Bremer, W., Love, J. S., O\u2019Donnell, N., Nelson, L. S., & Perrone, J. (2022). Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl. Clinical Toxicology, 60(6), 694\u2013701.","journal-title":"Clinical Toxicology"},{"key":"3729_CR69","doi-asserted-by":"crossref","unstructured":"Varshneya, N. B., Thakrar, A. P., Hobelmann, J. G., Dunn, K. E., & Huhn, A. S. (2022). Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. Journal of Addiction Medicine.","DOI":"10.1097\/ADM.0000000000000922"},{"issue":"5","key":"3729_CR70","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1037\/pha0000510","volume":"29","author":"T Nalven","year":"2021","unstructured":"Nalven, T., Spillane, N. S., Schick, M. R., & Weyandt, L. L. (2021). Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review. Experimental and Clinical Psychopharmacology, 29(5), 524.","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"2","key":"3729_CR71","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1370\/afm.516","volume":"4","author":"M Fortin","year":"2006","unstructured":"Fortin, M., Dionne, J., Pinho, G., Gignac, J., Almirall, J., & Lapointe, L. (2006). Randomized controlled trials: Do they have external validity for patients with multiple comorbidities? The Annals of Family Medicine, 4(2), 104\u2013108.","journal-title":"The Annals of Family Medicine"},{"issue":"12","key":"3729_CR72","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1111\/jgs.16875","volume":"68","author":"ND Forsat","year":"2020","unstructured":"Forsat, N. D., Palmowski, A., Palmowski, Y., Boers, M., & Buttgereit, F. (2020). Recruitment and retention of older people in clinical research: A systematic literature review. Journal of the American Geriatrics Society, 68(12), 2955\u20132963.","journal-title":"Journal of the American Geriatrics Society"},{"issue":"8","key":"3729_CR73","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s10067-017-3703-9","volume":"36","author":"T Patton","year":"2017","unstructured":"Patton, T., Bojke, L., Walton, M., Manca, A., & Helliwell, P. (2017). Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: Can we make better use of patient data registries? Clinical Rheumatology, 36(8), 1803\u20131810.","journal-title":"Clinical Rheumatology"},{"key":"3729_CR74","doi-asserted-by":"crossref","unstructured":"Alexander, H., Patton, T., Jabbar-Lopez, Z. K., Manca, A., & Flohr, C. (2019). Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution? F1000Research, 8.","DOI":"10.12688\/f1000research.17039.1"},{"issue":"6","key":"3729_CR75","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1177\/2167702619855659","volume":"7","author":"BD Kiluk","year":"2019","unstructured":"Kiluk, B. D., Yip, S. W., DeVito, E. E., Carroll, K. M., & Sofuoglu, M. (2019). Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder. Clinical Psychological Science, 7(6), 1190\u20131206.","journal-title":"Clinical Psychological Science"},{"issue":"3","key":"3729_CR76","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","volume":"20","author":"O Ciani","year":"2017","unstructured":"Ciani, O., Buyse, M., Drummond, M., Rasi, G., Saad, E. D., & Taylor, R. S. (2017). Time to review the role of surrogate end points in health policy: State of the art and the way forward. Value in Health, 20(3), 487\u2013495.","journal-title":"Value in Health"},{"issue":"7","key":"3729_CR77","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40273-021-01018-5","volume":"39","author":"S Harvard","year":"2021","unstructured":"Harvard, S., & Werker, G. R. (2021). Health economists on involving patients in modeling: Potential benefits, harms, and variables of interest. Pharmacoeconomics, 39(7), 823\u2013833.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"3729_CR78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40258-015-0200-7","volume":"14","author":"GA van Voorn","year":"2016","unstructured":"van Voorn, G. A., Vemer, P., Hamerlijnck, D., Ramos, I. C., Teunissen, G. J., Al, M., & Feenstra, T. L. (2016). The missing Stakeholder Group: Why patients should be involved in health economic modelling. Applied Health Economics and Health Policy, 14(2), 129\u2013133.","journal-title":"Applied Health Economics and Health Policy"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03729-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-024-03729-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03729-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T11:14:28Z","timestamp":1728040468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-024-03729-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":78,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3729"],"URL":"https:\/\/doi.org\/10.1007\/s11136-024-03729-6","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"24 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of the University of California San Diego determined that an ethics review was not required because this study relied on the use of secondary de-identified data (Project #805662).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"CM reported having stock options in CARI Health and received payments for consultancy services from CARI Health (both unrelated to the submitted work). NKM received unrestricted research grants awarded to her university from Gilead (unrelated to the submitted work). JRB is Co-Editor in Chief of Quality of Life Research and is not part of the decision-making process for this manuscript. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}